Long noncoding RNA PCAT1 regulates extrahepatic cholangiocarcinoma progression via the Wnt/β-catenin-signaling pathway

Zhang, Fumin; Wu, Ming; Xu, Yi; Li, Zhenglong; Leng, Kaiming; Kang, Pengcheng; Cui, Yunfu; Jiang, Xingming

doi:10.1016/j.biopha.2017.07.025

Cited by 66 publications

(62 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…By employing a multiple screening phase including training and validation sets, we found that only PCAT1, MALAT1, and CPS1-IT1 were differentially expressed in HC (increased). Upregulated PCAT1 in HC tumor tissues acts as a competing endogenous for miR-122, increasing levels of glycogen synthase kinase 3β and decreasing β-catenin levels in whole cell lysates and nuclear fractions, indicating that PCAT1 silencing inhibited Wnt/β-catenin-signaling, promoting cell invasion [28,29]. LncRNA MALAT1 also promotes HC cell proliferation and invasion by activating the PI3K/Akt pathway [29].…”

Section: Discussionmentioning

confidence: 99%

The Plasma LncRNA Acting as Fingerprint in Hilar Cholangiocarcinoma

Shi

Zhang

et al. 2018

Cell Physiol Biochem

View full text Add to dashboard Cite

Background & Aims: Current studies have indicated that long non-coding RNAs (lncRNAs) could act as tumor biomarkers for disease diagnosis and prognosis prediction. In this study, we mainly focused on determining the expression of circulating lncRNAs in patients suffering for hilar cholangiocarcinoma (HC), aiming to reveal the potential lncRNA as a fingerprint. Methods: A total 12 lncRNAs were previously proven to be aberrantly expressed in HC tumor tissues. All of the 12 lncRNAs were selected as candidate targets for subsequent circulating lncRNA assay. The candidate lncRNAs were validated by qRT-PCR arranged in training and validation sets. The risk score analysis was employed. Data was presented with receiver operating characteristic curve (ROC). Results: Circulating PCAT1, MALAT1, and CPS1-IT1 were significantly increased in plasma samples of HC patients in both the training set and validation set. Through ROC analysis, we found that the three plasmatic lncRNAs presented the area under ROC curve value (AUC) as 0.784, 0.860, and 0.677. Further combination with the three factors indicated a higher power (AUC, 0.893; sensitivity, 85.5%; specificity, 93.2%). Conclusion: This was the first time to reveal the potential circulating fingerprints for predicting HC. PCAT1, MALAT1, and CPS1-IT1 may act as novel early diagnosis biomarkers for predicting HC.

show abstract

Section: Discussionmentioning

confidence: 99%

The Plasma LncRNA Acting as Fingerprint in Hilar Cholangiocarcinoma

Shi

Zhang

et al. 2018

Cell Physiol Biochem

View full text Add to dashboard Cite

show abstract

“…A recent report revealed that PCAT1 silencing could inhibit Wnt/β-catenin signaling via miR-122 repression and WNT1 expression in extrahepatic cholangiocarcinoma. 46 The activation of Wnt/β-catenin signaling can increase the proliferation activity of MM cells, thereby promoting the growth, survival, and migration of MM cells. 47 It is possible that there is a similar PCAT1/miR-122/WNT1/Wnt/β-catenin signaling axis in MM, which requires further studies.…”

Section: Pcat1mentioning

confidence: 99%

The role of long non‐coding RNAs in multiple myeloma

Cui

Song

Fang

2019

European J of Haematology

View full text Add to dashboard Cite

Multiple myeloma (MM) is still an incurable disease, and its pathogenesis involves cytogenetics and epigenetics. In recent years, the roles of long non‐coding RNAs (lncRNAs) in MM have been deeply studied by scholars. LncRNAs are defined as a class of non‐protein‐coding transcripts greater than 200 nucleotides in length, which are involved in a large spectrum of biological processes, including proliferation, differentiation, apoptosis, invasion, and chromatin remodeling. However, little is known about the specific mechanisms of these lncRNAs. They can act as oncogenic and/or tumor‐suppressive factors in the development and progression of MM. But that how do they work remains unclear. In this review, the recent progress in the study of functional lncRNAs associated with MM was summarized and the present knowledge about their expression and roles was discussed, to provide guidance for the in‐depth functional study of lncRNAs.

show abstract

“…LncRNA TLINC increases cancer cell migration [50]. In ECC, LncRNA PCAT1 is upregulated, promoting cancer cell proliferation, metastasis and inhibiting apoptosis [51]. The upregulated lncRNAs in CCA and their functions in cancer progression were also summarized in Table 1.…”

Section: Lncrna Promotes Cca Proliferation Migration and Invasionmentioning

confidence: 99%

“…Inhibition of Wnt signaling in animal models can markedly reduce cancer cell proliferation and increase apoptosis, resulting in tumor regression [58]. LncRNA PCAT1 is reported to activate Wnt/β-catenin signaling and promote ECC progression [51]. Recent studies further demonstrate that lncRNA may participate in the pathogenesis of CCA in a Wnt pathway dependent manner [51,59].…”

Section: Lncrna Activates Oncogenic Signaling Pathways In Cca Developmentioning

confidence: 99%

“…LncRNA PCAT1 is reported to activate Wnt/β-catenin signaling and promote ECC progression [51]. Recent studies further demonstrate that lncRNA may participate in the pathogenesis of CCA in a Wnt pathway dependent manner [51,59]. For example, transcribed-ultraconserved regions (T-UCRs, a group of lncRNAs that harbor ultraconserved fragments) were proved to be the downstream mediators of the Wnt/β-catenin pathway, which was upregulated considerately in human CCA tissues [59].…”

Section: Lncrna Activates Oncogenic Signaling Pathways In Cca Developmentioning

confidence: 99%

See 1 more Smart Citation

The Advancement of Long Non-Coding RNAs in Cholangiocarcinoma Development

Jiang¹,

Ling²

2019

J. Cancer

View full text Add to dashboard Cite

Cholangiocarcinoma (CCA) is a malignancy with increasing incidence in recent years. CCA patients are usually diagnosed at advanced stage due to lack of apparent symptoms and specifically diagnostic markers. Nowadays, surgical removal is the only effective method for CCA whereas overall 5-year-survival rate keeps around 10%. Long-noncoding RNA (lncRNA), a subtype of noncoding RNA, is widely studied to be abnormally expressed in multiple cancers including CCA. LncRNA can promote proliferation, migration, invasion and inhibit apoptosis of CCA. Moreover, lncRNA is negatively correlated with the prognosis of CCA. LncRNA may contribute to the development of CCA via modulating gene transcription, sponging microRNA, regulating CCA-related signaling pathways or protein expression. LncRNA is thought to be potential diagnostic markers and therapeutic targets for CCA.

show abstract

Long noncoding RNA PCAT1 regulates extrahepatic cholangiocarcinoma progression via the Wnt/β-catenin-signaling pathway

Cited by 66 publications

References 31 publications

The Plasma LncRNA Acting as Fingerprint in Hilar Cholangiocarcinoma

The Plasma LncRNA Acting as Fingerprint in Hilar Cholangiocarcinoma

The role of long non‐coding RNAs in multiple myeloma

The Advancement of Long Non-Coding RNAs in Cholangiocarcinoma Development

Contact Info

Product

Resources

About